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Eff ectiveness of a monovalent rotavirus vaccine in infants in 
Malawi after programmatic roll-out: an observational and 
case-control study
Naor Bar-Zeev, Lester Kapanda, Jacqueline E Tate, Khuzwayo C Jere, Miren Iturriza-Gomara, Osamu Nakagomi, Charles Mwansambo, 
Anthony Costello, Umesh D Parashar, Robert S Heyderman, Neil French, Nigel A Cunliff e, for the VacSurv Consortium*
Summary
Background Rotavirus is the main cause of severe acute gastroenteritis in children in Africa. Monovalent human 
rotavirus vaccine (RV1) was added into Malawi’s infant immunisation schedule on Oct 29, 2012. We aimed to assess 
the impact and eff ectiveness of RV1 on rotavirus gastroenteritis in the 2 years after introduction.
Methods From Jan 1, 2012, to June 30, 2014, we recruited children younger than 5 years who were admitted into 
Queen Elizabeth Central Hospital, Blantyre, Malawi, with acute gastroenteritis. We assessed stool samples from these 
children for presence of rotavirus with use of ELISA and we genotyped rotaviruses with use of RT-PCR. We compared 
rotavirus detection rates in stool samples and incidence of hospital admittance for rotavirus in children from Jan 1 to 
June 30, in the year before vaccination (2012) with the same months in the 2 years after vaccination was introduced 
(2013 and 2014). In the case-control portion of our study, we recruited eligible rotavirus-positive children from the 
surveillance platform and calculated vaccine eff ectiveness (one minus the odds ratio of vaccination) by comparing 
infants with rotavirus gastroenteritis with infants who tested negative for rotavirus, and with community age-matched 
and neighbourhood-matched controls. 
Findings We enrolled 1431 children, from whom we obtained 1417 stool samples (99%). We detected rotavirus in 
79 of 157 infants (50%) before the vaccine, compared with 57 of 219 (40%) and 52 of 170 (31%) in successive calendar 
years after vaccine introduction (p=0·0002). In the fi rst half of 2012, incidence of rotavirus hospital admission was 
269 per 100 000 infants compared with 284 in the same months of 2013 (rise of 5·8%, 95% CI –23·1 to 45·4; p=0·73) 
and 153 in these months in 2014 (a reduction from the prevaccine period of 43·2%, 18·0–60·7; p=0·003). We 
recruited 118 vaccine-eligible rotavirus cases (median age 8·9 months; IQR 6·6–11·1), 317 rotavirus-test-negative 
controls (9·4 months; 6·9–11·9), and 380 community controls (8·8 months; 6·5–11·1). Vaccine eff ectiveness for two 
doses of RV1 in rotavirus-negative individuals was 64% (95% CI 24–83) and community controls was 63% (23–83). 
The point estimate of eff ectiveness was higher against genotype G1 than against G2 and G12.
Interpretation Routine use of RV1 reduced hospital admissions for several genotypes of rotavirus in children 
younger than 5 years, especially in infants younger than 1 year. Our data support introduction of rotavirus 
vaccination at the WHO recommended schedule, with continuing surveillance in high-mortality countries.
Funding Wellcome Trust, GlaxoSmithKline Biologicals.
Copyright © Bar-Zeev, et al. Open Access article distributed under the terms of CC BY.
Introduction
Rotavirus is the leading cause of severe acute gastro-
enteritis in infants and young children worldwide, 
causing about 453 000 child deaths every year before the 
introduction of the rotavirus vaccine.1 Widespread use of 
two orally administered, live attenuated rotavirus vaccines 
(a monovalent human rotavirus vaccine [RV1] and a 
pentavalent human–bovine reassortant rotavirus vaccine 
[RV5]) in North, Central, and South America, Europe, and 
Australia has largely reduced hospital admissions for 
rotavirus gastroenteritis, and decreased child deaths from 
diarrhoea in Mexico, Brazil, and Panama.2–9
The greatest rotavirus burden, especially mortality, is in 
low-income countries in Africa and Asia. Clinical trials of 
RV1 and RV5 in Africa and Asia report lowest effi  cacy in 
the countries with the highest disease burden and lowest 
income.10–12 However, because of the high mortality from 
rotavirus gastroenteritis in such countries, in 2009 WHO 
recommended that all children should receive rotavirus 
vaccine, with a strong recommendation for countries 
where diarrhoeal diseases cause more than 10% of deaths.13
From January, 2012, to July, 2014, rotavirus vaccine was 
introduced in 19 countries in Africa.14 So far, no 
eff ectiveness data have been published from low-income 
countries in sub-Saharan Africa. Malawi is a very-low-
income southern African country with a mortality in 
children younger than 5 years of 71 per 1000 livebirths15 
and gross domestic product per person (purchasing-power 
parity) of US$900.16 With support from Gavi, the Vaccine 
Alliance, RV1 was introduced into Malawi’s Expanded 
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Programme on Immunisation on Oct 29, 2012. Two oral 
doses were scheduled to be given at 6 weeks and 10 weeks 
of age, without a catch-up campaign for older children. 
Building on previous studies of rotavirus gastroenteritis in 
Malawi, including a pivotal randomised placebo-controlled 
trial of RV1,10 we report observational data for the impact of 
a completed series of rotavirus vaccine against laboratory 
confi rmed incidence of rotavirus diarrhoea hospitalisation 
in Malawi. We also report results of a case-control study 
that aimed to establish vaccine eff ectiveness with use of 
rotavirus-negative infants and community controls.
Methods
Study design
We did a hospital-based surveillance study of rotavirus 
disease in children younger than 5 years at one hospital in 
Malawi. We then did a case-control study to establish 
vaccine eff ectiveness against rotavirus gastroenteritis by 
assessing vaccine status of patients with gastro enteritis 
cases who tested positive for rotavirus with those who 
tested negative and with community controls. Our 
primary endpoint was the eff ectiveness of a completed 
series of rotavirus vaccine against laboratory confi rmed 
rotavirus diarrhoea during routine vaccine use. Secondary 
endpoints were the genotype-specifi c eff ectiveness and 
the population impact of the RV1 vaccination programme.
Surveillance and genotyping
From Jan 1, 2012, to June 30, 2014, we did active 
surveillance for acute gastroenteritis at Queen Elizabeth 
Central Hospital (QECH), Blantyre, Malawi, which is the 
referral hospital for the southern region of Malawi. 
QECH is the only inpatient referral facility that provides 
free health care to Blantyre district’s 1 million residents. 
We en rolled children younger than 5 years who lived in 
Blantyre district and who presented at any time to 
the paediatric emergency department with acute gastro-
enteritis. Inclusion and exclusion criteria are contained 
in the appendix. 
With written parental consent, we obtained demographic, 
clinical, and anthropometric data with use of a standardised 
case report form (for study defi nitions see appendix). We 
measured gastroenteritis disease severity with a modifi ed 
Vesikari score.17 HIV status was established in fi nger-prick 
blood samples with two sequential antibody rapid tests 
(Determine, Abbott Laboratories, Germany, and Uni-Gold, 
Trinity Biotech, Ireland) or by DNA PCR in infants younger 
than 12 months, according to national guidelines.18 One 
stool sample was obtained for each child before discharge 
from the emergency department or within 48 h of hospital 
admission. We examined 10% faecal suspensions in 
phosphate buff ered saline for rotavirus with ELISA 
(Rotaclone, Meridian Bioscience, Cincinnati, OH, USA). 
Rotavirus VP7 (G) and VP4 (P) genotypes were established 
for ELISA-rotavirus-positive specimens with qualitative, 
heminested multiplex reverse transcription PCR onsite at 
the hospital campus.19
We compared rotavirus detection rate and hospital 
admission incidence for rotavirus for Jan 1 to June 30 in 
the year before vaccine introduction (2012) with those for 
the same period in the fi rst and second calendar year 
(Jan 1 to June 30, 2013 and 2014, respectively) after 
introduction. We calculated incidence of rotavirus 
hospital admissions as number of inpatient cases per 
100 000 Blantyre mid-year population under surveillance; 
estimated with age-specifi c population projections from 
the 2008 population census.20 We derived projections for 
population through linear extension of the annual 
increase in age-specifi c population in the intercensal 
period from 1998 to 2008.
Case-control study
In the same period, we also did a case-control study to 
establish vaccine eff ectiveness. From Oct 29, 2012, we 
recruited children with rotavirus gastroenteritis from 
Figure 1: Rotavirus gastroenteritis detection by month in Queen Elizabeth Central Hospital, Blantyre
(A) Number of rotavirus cases per month. (B) Proportion of stool samples positive for rotavirus.
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the surveillance platform who fulfi lled inclusion criteria 
(appendix) and who were vaccine age-eligible (6 weeks of 
age or older; born on or after Sept 17, 2012; thus were 
less than 6 weeks of age at introduction of vaccine). We 
recruited two control groups: unmatched vaccine age-
eligible infants attending QECH with acute gastro-
enteritis who were negative for rotavirus with ELISA, 
and diarrhoea-free control individuals from the 
community whom we chose through a random walk 
method and who were matched to cases by date of birth 
(30 days older or younger for infants younger than 1 year, 
and 3 months older or younger if the child was older 
than 1 year) and subdistrict ward of residence. We 
obtained vaccine status of cases and controls from the 
patient held medical record (health passport) with 
capture of a digital image. We excluded from analysis 
children whose parents reported vaccine status but did 
not have a written record. We measured the odds of 
being vaccinated in cases and respective controls, and 
adjusted for age at admission and month and year of 
birth in unmatched test-negative controls; no adjustment 
was made in the matched analysis. Vaccine eff ectiveness 
was calculated as one minus the odds ratio derived from 
logistic regression, which was conditional in the 
matched study but not otherwise.
Statistical analysis
We calculated that to assess the primary outcome using a 
case-control design, we needed 102 cases for 80% power 
to detect a vaccine eff ectiveness of at least 50% at two-
sided 5% signifi cance level, assuming vaccine coverage 
of 70%, a control to case ratio of four, and intracluster 
correlation coeffi  cient within the matched groupings of 
0·2.21 We did not do power calculations for secondary 
outcomes.
To calculate vaccine eff ectiveness, we subtracted the 
incidence rate ratio for rotavirus hospital admission for 
Jan 1 to June 30 in the year before vaccine introduction 
(2012) from one and compared this fi gure with the rate 
ratio for the same calendar months in the years after 
introduction (2013 and 2014).22 Additionally, to quantify 
the independent contribution of the vaccine programme 
to incidence over time, we used Poisson regression of 
rotavirus hospital admission incidence against vaccine 
coverage, adjusted for month of admission and stratifi ed 
by age group. We extrapolated vaccine coverage for 
infants in Blantyre from the coverage in the rotavirus-
test-negative infant cohort that we recruited. Vaccination 
coverage in children younger than 5 years assumed that 
children in the community not age eligible for vaccination 
were not vaccinated.
We tested diff erences in continuous covariates by t test 
or by Wilcoxon rank-sum test if not normally distributed 
based on normal quantile plots, and we examined 
categorical covariates with χ² test. We did trend analysis 
for proportions with Royston’s test.23 We did analyses 
with Stata 12·1.
Ethical approval was provided by the National Health 
Sciences Research Committee, Lilongwe, Malawi (867) 
and by the Research Ethics Committee of the University 
of Liverpool, Liverpool, UK (000490).
Figure 2: Rotavirus VP7 (G) genotypes detected by month in children younger than 5 years of age presenting 
to Queen Elizabeth Central Hospital, Blantyre, from Jan 1, 2012, to June 30, 2014
Graph excludes mixed infection.
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Rotavirus-
positive children 
(n=118)
Negative controls
(n=317)
Community controls (n=380)
Rotavirus-negative 
children
p for 
diff erence
Community 
controls
p for 
diff erence
Median age (months) 8·9 (6·1–11·1) 9·4 (6·9–11·9) 0·16* 8·8 (6·5–11·1) 0·81*
Median household size 4 (3–6) 5 (4–6) 0·31* 4 (3–5) 0·44
Median maternal age 26 (22–30) 25 (22–30) 0·70* 27 (21–30) 0·19*
Maternal orphan 4 (3%) 7 (2%) 0·50 0 0·01†
Paternal orphan 1 (1%) 3 (1%) 0·93 1 (0·3%) 0·40†
Preterm birth 
(<37 weeks)
5 (4%) 15 (5%) 0·81 ·· ··
Median birthweight (kg) 3·0 (2·8–3·5) 3·0 (2·7–3·3) 0·09 ·· ··
HIV exposed‡ 20 (17%) 66 (21%) 0·44 ·· ··
HIV infected 5 (4%) 14 (5%) 0·92 ·· ··
Currently breastfed 107 (91%) 286 (92%) 0·39 ·· ··
Exclusively breastfed 5 (4%) 16 (6%) 0·71 ·· ··
Mean weight for age 
Z score§
–1·3 (1·5) –1·7 (1·6) 0·05 –0·2 (1·2) <0·0001
Mean length for age 
Z score
0·4 (2·7) 0·2 (2·9) 0·60 –1·8 (1·9) <0·0001
Diarrhoea 118 (100%) 317 (100%) ·· 0 ··
Admitted inpatient 104 (89%) 286 (91%) 0·55 0 ··
Vesikari score 0·003¶
≤10 25 (21%) 11 (35%) ·· ·· ··
10–14 57 (49%) 139 (44%) ·· ·· ··
≥15 35 (30%) 64 (20%) ·· ·· ··
Mean Vesikari score 12·3 (3·4) 11·3 (3·5) 0·01 ·· ··
Verifi ed vaccination 
status
109 (93%) 283 (90%) 0·30 370 (97%) 0·03
(Table 1 continues on next page)
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Role of the funding source
The funders had no role in study design, collection, 
analysis and interpretation of data, writing of the report, 
or the decision to submit the paper for publication. We 
provided GlaxoSmithKline Biologicals SA with the 
opportunity to review a preliminary version of this 
manuscript for factual accuracy, but we were solely 
responsible for fi nal content and interpretation. The 
corresponding author had full access to all the data from 
the study and had fi nal responsibility for the decision to 
submit for publication.
Results
We enrolled 1431 children younger than 5 years 
(1018 infants <12 months of age) with diarrhoea, from 
whom we collected 1417 stool specimens (99%). In this 
cohort of children, 1188 (82%) were being breastfed, 257 
(18%) had been exposed to HIV, and 79 (6%) were 
infected with HIV (appendix). Among the specimens 
collected, most (872 [61%]) were from infants, and the 
most (1334 [94%]) were from children younger than 
2 years.
Before vaccine introduction (Jan 1, 2012, to Oct 28, 
2012), we collected 419 stool samples, of which 185 (44%) 
were positive for rotavirus (fi gure 1). After vaccine 
introduction (Oct 29, 2012, to June 30, 2014), we collected 
998 stool samples, of which 318 (32%) were rotavirus 
positive (fi gure 1, appendix). Of 472 rotaviruses we 
examined from Jan 1, 2012, to June 30, 2014, prevalent 
genotypes included G2P[4] (117; 25%), G1P[8] (101; 21%), 
G12P[6] (48; 10%), and G2P[6] (47; 10%). 122 (26%) 
rotaviruses contained mixed G or P types or both 
(appendix). Genotype G1 was most common in the fi rst 
year after the introduction of the vaccine, whereas 
genotype G2 dominated in the second year (fi gure 2).
The incidence analysis from January to June, 2012, 
2013, and 2014, included 66% of all rotavirus-confi rmed 
cases in infants and 66% of cases in children aged 
1–4 years. From Jan 1, 2012, to June 30, 2012 (before 
introduction), rotavirus was detected in 98 of 225 (44%) 
children younger than 5 years, compared with 144 of 
344 (42%; p=0·69) and 91 of 315 (29%; p<0·0001) children 
in the same months of 2013 and 2014, respectively (p for 
trend =0·0002). In the fi rst 6 months of 2012, we detected 
rotavirus in 79 of 157 infants (50%; younger than 1 year) 
with gastroenteritis, compared with 87 of 220 (40%; 
p=0·04) in the same period of 2013, and 52 of 169 (31%; 
p<0·0001) in the same period of 2014 (p for trend=0·0002). 
The median age of patients with rotavirus gastroenteritis 
(cases) before vaccine introduction was 9·6 months (IQR 
7·0–13·5), compared with 11·1 months (8·1–15·4) in 
2014 (p=0·0001; appendix).
In the fi rst 6 months of 2013, vaccine coverage in 
children younger than 5 years in Blantyre was 5%, rising 
to 18% in the fi rst 6 months of 2014. From Jan 1 to 
June 30, 2012 (before vaccine introduction), the incidence 
of rotavirus-associated hospital admission per 
100 000 children younger than 5 years was 120, compared 
with 178 during the same period in 2013 and 101 during 
the same period in 2014. In 2013, rotavirus hospital 
admissions were 49% higher (95% CI 13·6–94·2, 
p=0·004) than in 2012, but were 15% (–14·7 to 37·6, 
p=0·28) lower in 2014 than in 2012.
Mean vaccine coverage was 26% in infants who tested 
negative for rotavirus Jan 1 to June 30, 2013, rising to 
92% for the equivalent period in 2014. In January to 
June, 2012, incidence of rotavirus hospital admission per 
100 000 infants was 269, whereas it was 284 in the same 
months of 2013 (rise of 5·8%, 95% CI –23·1 to 45·4; 
p=0·73) and 153 in these months in 2014 (a reduction 
from the prevaccine period of 43·2%, 18·0–60·7; 
p=0·003; appendix). Poisson regression of incidence of 
Rotavirus-
positive children 
(n=118)
Negative controls (n=317) Community controls (n=380)
Rotavirus-negative 
children
p for 
diff erence
Community 
controls
p for 
diff erence
(Continued from previous page)
Vaccine coverage among children with verifi ed vaccination status
Rotavirus vaccine 0·03‡ 0·04¶
0 doses 16 (15%) 17 (6%) ·· 28 (8%) ··
1 dose 9 (8%) 30 (11%) ·· 42 (12%) ··
2 doses 81 (75%) 234 (83%) ·· 286 (80%) ··
Missing data 2 1 ·· 2 ··
Median age at 
dose 2 (weeks)
12·4
(11·1–15·3)
12·0
(10·9–15·9)
0·46* 12·8 
(11·0–14·6)
0·45*
Pentavalent vaccine 0·82‡ 0·63‡
0 doses 2 (2%) 4 (1%) ·· 6 (2%) ··
1 dose 6 (6%) 14 (5%) ·· 19 (5%) ··
2 doses 6 (6%) 26 (9%) ·· 43 (12%) ··
3 doses 94 (87%) 235 (83%) ·· 288 (78%) ··
Missing data 0 3 ·· 14 ··
Oral polio vaccine 
(birth dose)
83 (77%) 207 (73%) 0·49 283 (76%) 0·14
Oral polio vaccine 0·85¶ 0·61‡
0 doses 2 (2%) 4 (1%) ·· 10 (3%) ··
1 dose 7 (6%) 16 (6%) ·· 27 (7%) ··
2 doses 15 (14%) 42 (15%) ·· 50 (14%) ··
3 doses 84 (78%) 219 (78%) ·· 269 (73%) ··
Missing data 0 1 ·· 14 ··
Pneumococcal vaccine 0·64¶ 0·06‡
0 doses 0 3 (1%) ·· 7 (2%) ··
1 dose 4 (4%) 7 (3%) ·· 22 (6%) ··
2 doses 8 (7%) 28 (10%) ·· 41 (11%) ··
3 doses 91 (84%) 233 (83%) ·· 286 (77%) ··
Missing data 5 11 ·· 14 ··
BCG vaccine 104 (96%) 272 (96%) 0·80 346 (94%) 0·18
Measles vaccine 32 (29%) 96 (34%) 0·37 113 (31%) 0·88
Data are median (IQR), n (%), or mean (SD), unless otherwise shown. *Wilcoxon rank-sum test. †Fisher’s exact test. 
‡HIV exposed is defi ned in appendix. §Anthropometry at presentation to hospital or at recruitment in the community. 
¶Mantel-Haenszel χ2 test.
 Table 1: Demographic and clinical characteristics of children
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rotavirus hospital admission in infants against 
population vaccine coverage for the entire surveillance 
period Jan 1, 2012, to June 30, 2014, and adjusted for 
calendar year and month, showed a reduction in 
incidence of 6·6% (3·7–9·5; p<0·0001) for a 10% 
increase in vaccination coverage. Incidence in children 
aged 1–4 years fell by 10·9% (–7·7 to 29·1; p=0·25; 
appendix).
For the case-control portion of our study, we recruited 
118 vaccine-eligible children with rotavirus gastroenteritis 
(median age 8·9 months, IQR 6·1–11·1, range 2·5–17·0), 
317 rotavirus-test-negative children with gastroenteritis 
(9·4 months, 6·9–11·9, 2·3–18·0), and 380 community 
controls (8·8 months, 6·5–11·1, 1·4–18·2; table 1). 
Sociodemographic characteristics of recruited children 
did not diff er between cases and controls (table 1). 
109 children (93%) with rotavirus had a vaccine record, as 
did 283 (90%) of rotavirus-test-negative controls and 
370 (97%) community controls. Age of rotavirus vaccine 
receipt did not diff er between children with rotavirus and 
those without (table 1). 87% of infants received dose one 
by 10 weeks and 98% within the nationally mandated 
limit of 15 weeks; 78% received dose two by 14 weeks and 
none received dose two beyond 26 weeks (appendix). 
Vaccine coverage did not signifi cantly diff er between 
children with rotavirus and either control group for any 
antigen except for rotavirus (table 1).
Vaccine eff ectiveness for two doses of RV1 was 64% 
(95% CI 24–83) in test-negative control individuals and 
63% (23–83) in community controls (table 2). For 
children with more severe disease (Vesikari score ≥11), 
eff ectiveness for two doses of RV1 was 68% (95% CI 
22–87) in test-negative control individuals and 68% 
(23–86) in community controls (table 2). The two-dose 
vaccine eff ectiveness point estimate was higher for 
rotavirus G1 (82% [42–95] and 78% [8–95] for test-
negative and community controls, respectively), than for 
rotavirus G2 (53% [–28 to 83] and 61% [–29 to 88], 
respectively), or for rotavirus G12 (53% [–99 to 89] and 
61% [–208 to 95], respectively; table 2).
Discussion
We show that RV1 reduces the number of hospital 
admissions for acute rotavirus gastroenteritis in 
Malawi, one of the fi rst African countries with high 
rotavirus-associated mortality to implement routine 
infant vaccination for rotavirus. We detected vaccine 
eff ective ness that was at least equal to that reported in 
the RV1 effi  cacy trial in Malawi.10 In the fi rst year after 
vaccine introduction, a sharp rise occurred in hospital 
admissions for rotavirus in children younger than 
5 years, but there was no signifi cant increase in infants, 
implying vaccine eff ect at low vaccine coverage. By 
2014, vaccine coverage in infants was high, and the 
peak incidence during that period was lower than in 
previous periods. Adjusting for month, we also show 
an independent inverse dose–response relation 
between increasing population vaccine coverage and 
incidence of rotavirus hospital admission in infants; 
this was not present in older children in whom 
population coverage occurred later and was much 
lower. The sustained and more pronounced reduction 
in rotavirus hospital admission rate and detection rate 
in the second year after vaccine introduction in 2014, 
largest in infants, together with a shift in age 
distribution of rotavirus cases by the second year after 
vaccine introduction when vaccine coverage was high, 
suggests early vaccine impact.
Rotavirus-
positive 
children
Rotavirus test-negative 
controls
Community controls
Patients Adjusted vaccine 
eff ectiveness*
Patients Vaccine 
eff ectiveness†
Children eligible for dose 2
Number for 
assessment
109 283 ·· 356 ··
Median age 
(months)
8·2 
(6·6–10·9)
9·0 
(6·6–11·6)
·· 8·2 
(6·5–11·0)
··
Number of doses
0 doses 16 (15%) 17 (6%) Ref 28 (8%) Ref
2 doses 81 (74%) 234 (83%) 64% (24–83) 286 (80%) 63% (23–83)
>1 dose 90 (83%) 264 (94%) 65% (27–83) 328 (90%) 68% (42–83)
Children with Vesikari score ≥11
Number for 
assessment
90 197 ·· 288 ··
Median age 
(months)
8·6 
(6·6–11·0)
9·5 
(7·3–11·4)
·· 8·6 
(6·5–11·0)
··
Number of doses
0 doses 13 (14%) 10 (5%) Ref 19 (7%) Ref
2 doses 69 (77%) 195 (89%) 68% (22–87) 239 (83%) 68% (23–86)
>1 dose 77 (89%) 208 (95%) 69% (25–87) 269 (91%) 68% (37–83)
Non-mixed G1 rotavirus infection
Number for 
assessment
21 283 ·· 66 ··
Number of doses
0 doses 5 (24%) 18 (6%) Ref 6 (9%) Ref
2 doses 12 (57%) 234 (83%) 82% (42–95) 53 (80%) 78% (8–95)
Non-mixed G2 rotavirus infection
Number for 
assessment
50 283 ·· 167 ··
Number of doses
0 doses 6 (12%) 18 (6%) Ref 11 (7%) Ref
2 doses 38 (76%) 234 (83%) 53% (–28 to 83) 135 (81%) 61% (–29 to 88)
Non-mixed G12 rotavirus infection
Number for 
assessment
18 283 ·· 48 ··
Number of doses
0 doses 3 (17%) 18 (6%) Ref 5 (10%) Ref
2 doses 14 (78%) 234 (83%) 53% (–99 to 89) 34 (71%) 61% (–208 to 95)
Data are n (%), median (IQR), and vaccine eff ectiveness (95% CI). *Adjusted for age at admission and month and year 
of birth. †Restricted to controls that were matched within 30 days before or after the case’s date of birth if they were 
younger than 1 year and 3 months if they were older than 1 year. 
 Table 2: Rotavirus vaccine eff ectiveness by dose of rotavirus vaccine
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Our fi nding of eff ectiveness with a 6 and 10 week of 
age schedule of vaccination, with each dose given in a 
timely fashion during programmatic roll-out (appendix), 
strongly supports use of this schedule as recommended 
by WHO.13 The degree of protection aff orded by this 
schedule had not been established previously because 
RV1 doses were given at 10 and 14 weeks of age in the 
African effi  cacy trial and at 6 and 14 weeks in an 
eff ectiveness study in South Africa (panel).10,24 Indeed in 
a 2010 study in South Africa, the immunogenicity of two 
RV1 doses given at 6 and 10 weeks of age was lower than 
that of two doses given at 10 and 14 weeks (seroconversion 
36% vs 60%, respectively).25 Confi rmation of vaccine 
eff ectiveness with schedule at 6 and 10 weeks of age is 
especially important in infants in low-income countries 
such as Malawi, in which three-quarters of the total 
rotavirus disease burden is sustained in the fi rst year of 
life and early protection is needed.26,27
We show robust eff ectiveness of the G1P[8] RV1 vaccine 
despite genotypic rotavirus diversity in the population, 
with fully homotypic (G1P[8]), fully heterotypic (G2P[4], 
G2P[6], and G12P[6]), and partially heterotypic (G12P[8]) 
genotypes circulating during the study. However, the 
point estimate for vaccine eff ectiveness was higher 
against G1 than against G12 or G2 genotypes. In the 
second year after vaccine introduction the number of 
cases of gastroenteritis associated with rotavirus 
genotypes G1 and G12 decreased, but infections with G2 
persisted. Although our study was not powered to assess 
strain-specifi c diff erences in vaccine eff ectiveness, these 
data underscore the need for further surveillance to 
address the potential for lower vaccine eff ectiveness 
against fully heterotypic genotypes including G2P[4],28,29 
particularly since previous fi ndings suggested that RV1 
leads to cross-genotype protection in this and other 
populations.30
The point estimate of vaccine eff ectiveness (64% for 
hospital-test-negative controls and 63% for community 
controls) is at the upper limit of that reported by 
investigators of a randomised trial of RV1 (vaccine 
eff ectiveness 49%, 95% CI 19–68) in the same setting in 
Malawi. Similar magnitudes of vaccine eff ectiveness 
were established by comparisons with hospital and 
community controls. Notably, our study was done in the 
2 years immediately after vaccine introduction and thus 
our population was enriched with young infants in 
whom vaccine eff ectiveness might be greatest; further 
surveillance of children after 2 years of age will be 
important since protection has been postulated to wane 
in the second year in low-income settings, although 
recent studies in South Africa showed sustained 
protection in the second year of life.24,31
Our study has limitations. First, although we show a 
dose–response relation between population vaccine 
coverage and reductions in disease incidence that is 
independent of time, the incidence analysis was based on 
population denominator projections from census data 
that are 4 and 14 years old and the numerator assumes no 
change in health-seeking behaviour. Although both 
measurements will include error, the nature of the error 
should be consistent over time and not aff ected by RV1 
introduction. Nonetheless these data should be 
interpreted cautiously, based as they are on a short period 
of observation before vaccine introduction and the 
observation of low incidence during the prevaccine 
period in older children. Second, our case-control 
analysis examined only the direct protection provided by 
vaccination. The total benefi t of a national rotavirus 
vaccine programme is probably greater than that 
provided by direct protection, as has been noted in other 
settings after rotavirus vaccine introduction.32,33 Blantyre 
is an urban site with periurban rural areas. Our results 
might not be representative of sociodemographically or 
economically diff ering settings. 
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Panel: Research in context
Systematic review
We searched Medline using the following query “rotavirus vaccin* AND (effi  cacy OR 
eff ectiveness OR impact) NOT cost-eff ectiveness” restricted to studies in children 
published in English in the past 10 years. A randomised controlled trial reported 
effi  cacy for the monovalent rotavirus vaccine against severe acute rotavirus 
gastroenteritis in Malawi. Post-introduction population eff ectiveness has been shown 
in high-income and middle-income countries in Europe; North, South, and Central 
America; Australia; and recently in South Africa. However, no data have been reported 
from low-income countries in sub-Saharan Africa where there are high burdens of 
rotavirus gastroenteritis and mortality. Furthermore, no study has shown the 
eff ectiveness of rotavirus vaccine given at the WHO-recommended accelerated 
schedule of 6 and 10 weeks of age.
Interpretation
Data are needed to establish defi nitively the WHO-recommended schedule in high-
burden low-income sub-Saharan African countries that are eligible for Gavi-supported 
vaccine introduction. We present the fi rst such evidence for the eff ect of the monovalent 
rotavirus vaccine on rotavirus-associated hospital admissions and present results for a 
broad range of rotavirus genotypes. Our fi ndings show that in the context of high vaccine 
coverage in Malawi, the promising data from vaccine effi  cacy trials have translated into 
programmatic reductions in rotavirus hospitalisations in a high-disease burden infant 
population. These data strongly support the continued roll-out of rotavirus vaccines in 
other low-income countries in Africa and Asia.
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